Candel Therapeutics Inc (CADL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $486.37M
Last updated: Nov 17, 2026 at 11:04 AM ET
Candel Therapeutics Inc (CADL) Stock Forecast
Analysts expect Candel Therapeutics (CADL) to earn -$1.08 per share in the fiscal year ending Dec 31, 2026. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 10 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$1.08
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.63
- EPS consensus, revenue $41.92M
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.08 | -$1.28 to -$0.74 | 3 | N/A | N/A | 8 |
| Dec 31, 2027 | -$0.63 | -$1.47 to $0.22 | 2 | $41.92M | N/A | 9 |
Quarterly Estimates
The EPS consensus rises from -$0.38 for the quarter ending Dec 31, 2026 to -$0.32 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.38 | -$0.60 to -$0.08 | 12 |
| Mar 31, 2027 | -$0.32 | -$0.32 to -$0.32 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.87.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.08 | -$1.08 | -$1.00 | -$0.90 | -$0.87 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.63 | -$0.63 | -$0.63 | -$0.61 | $0.22 | N/A |
| Quarter ending Mar 31, 2027 | -$0.32 | -$0.32 | -$0.32 | N/A | N/A | N/A |
Frequently Asked Questions About CADL
What is the CADL stock forecast?
Consensus analyst estimates put Candel Therapeutics's EPS at -$1.08 for the fiscal year ending Dec 31, 2026. The consensus rating from 10 analysts is Buy.
How do analysts rate CADL stock?
Of 10 analysts covering Candel Therapeutics, 0 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CADL next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.08, with estimates from -$1.28 to -$0.74 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.63, with estimates from -$1.47 to $0.22 from 2 analysts.
What revenue do analysts expect from Candel Therapeutics next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $41.92M.
How many analysts cover CADL?
10 analysts rate Candel Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CADL pages: Overview, Earnings, Forecast, Financials, Competitors